Literature DB >> 9027320

Characteristics of tumor cell bioactivity in oncogenic osteomalacia.

A E Nelson1, H J Namkung, J Patava, M R Wilkinson, A C Chang, R R Reddel, B G Robinson, R S Mason.   

Abstract

Oncogenic osteomalacia is a condition where renal phosphate wasting occurs causing defective mineralisation, in the presence of a tumor. Cultures of cells were established from a hemangiopericytoma resected from a patient with oncogenic osteomalacia. Conditioned media from the cells inhibited phosphate uptake in opossum kidney cells and stimulated of cAMP in rat osteosarcoma cells, a standard parathyroid hormone (PTH)-like assay. This cAMP stimulation was suppressed by the PTH analogue, 3-34 bPTH and also by heat and trypsin treatment of the media. Tests of conditioned media for PTH and parathyroid hormone related protein (PTHrP) immunoreactivity were negative, however, and no hybridisation to probes for PTH, PTHrP or human stanniocalcin was detected in tumor cell RNA on Northern blot. These data support the hypothesis that tumors responsible for oncogenic osteomalacia produce a humoral substance that reduces renal phosphate reabsorption and provide evidence that the factor may act via PTH/PTHrP receptors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9027320     DOI: 10.1016/s0303-7207(96)03928-7

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  11 in total

Review 1.  Hypophosphatemic rickets.

Authors:  L A DiMeglio; M J Econs
Journal:  Rev Endocr Metab Disord       Date:  2001-04       Impact factor: 6.514

Review 2.  The molecular background to hypophosphataemic rickets.

Authors:  P S Rowe
Journal:  Arch Dis Child       Date:  2000-09       Impact factor: 3.791

3.  Serum MEPE-ASARM-peptides are elevated in X-linked rickets (HYP): implications for phosphaturia and rickets.

Authors:  Doron Bresler; Jan Bruder; Klaus Mohnike; William D Fraser; Peter S N Rowe
Journal:  J Endocrinol       Date:  2004-12       Impact factor: 4.286

4.  Stanniocalcin 1 and ovarian tumorigenesis.

Authors:  Guangzhi Liu; Gong Yang; Bin Chang; Imelda Mercado-Uribe; Miao Huang; Jingfang Zheng; Robert C Bast; Sue-Hwa Lin; Jinsong Liu
Journal:  J Natl Cancer Inst       Date:  2010-05-18       Impact factor: 13.506

Review 5.  Craniofacial hemangiopericytoma associated with oncogenic osteomalacia: case report.

Authors:  F A Sandhu; R L Martuza
Journal:  J Neurooncol       Date:  2000       Impact factor: 4.130

6.  Surface plasmon resonance (SPR) confirms that MEPE binds to PHEX via the MEPE-ASARM motif: a model for impaired mineralization in X-linked rickets (HYP).

Authors:  Peter S N Rowe; Ian R Garrett; Patricia M Schwarz; David L Carnes; Eileen M Lafer; Gregory R Mundy; Gloria E Gutierrez
Journal:  Bone       Date:  2004-11-24       Impact factor: 4.398

7.  Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia.

Authors:  T Shimada; S Mizutani; T Muto; T Yoneya; R Hino; S Takeda; Y Takeuchi; T Fujita; S Fukumoto; T Yamashita
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-08       Impact factor: 11.205

Review 8.  Inorganic phosphate homeostasis and the role of dietary phosphorus.

Authors:  Eiji Takeda; Hironori Yamamoto; Kunitaka Nashiki; Tadatoshi Sato; Hidekazu Arai; Yutaka Taketani
Journal:  J Cell Mol Med       Date:  2004 Apr-Jun       Impact factor: 5.310

Review 9.  The wrickkened pathways of FGF23, MEPE and PHEX.

Authors:  Peter S N Rowe
Journal:  Crit Rev Oral Biol Med       Date:  2004-09-01

10.  Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agent.

Authors:  Theresa Berndt; Theodore A Craig; Ann E Bowe; John Vassiliadis; David Reczek; Richard Finnegan; Suzanne M Jan De Beur; Susan C Schiavi; Rajiv Kumar
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.